Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N-acyl-1-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains.
Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N-acyl-1-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains.
Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5%. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 'H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Q-2 and Q-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.
Teicoplanin (9) is a glycopeptide antibiotic that consists of a mixture of five major components designated A2-1, A2-2, A2-3, A2-4, and A2-5 and one more polar component designated A3-1 (5); minor components are also present (4, 8) . All teicoplanin components are glycopeptide analogs with molecular weights that range from 1564.3 to 1907.7. The A3-1 component is the core glycopeptide that is common to all teicoplanin components that have been identified; it has a linear heptapeptide aglycone, an a-D-mannose, and an acetyl-o-D-glucosamine. All the components of the A2 group contain an additional N-acyl-p-D-glucosamine and differ only in the nature of this acyl-aliphatic chain (1, 4, 8) (Fig. 1 ). Teicoplanin components can be separated by gradient reversed-phase high-pressure liquid chromatography (HPLC) (Fig. 2) (13) , by which it has been found that the A3-1 component is more polar than the A2 group components.
Recovery studies with radiolabeled teicoplanin in rats (2, 16) and humans (7) following intravenous (i.v.) administration showed that the antibiotic is eliminated mainly by the renal route. In rats, approximately 70% of the administered dose is eliminated in 24 h, and 76% is eliminated in 120 h (2). In humans, elimination is slower; approximately 50% of the administered dose is recovered in the urine collected over 0 to 48 h after drug administration and 80% is recovered by 16 days (7). A study in rats with i.v. administration of teicoplanin showed little metabolic transformation of the antibiotic; in urine collected over 0 to 24 h after drug administration, no more than 3 to 5% of the dose eliminated was found to be metabolized (17) . In humans, following i.v. administration of teicoplanin, the pharmacokinetics of the individual components of teicoplanin were studied by reversed-phase HPLC.
The cumulative amount of A3-1 recovered in urine 9 days after administration of teicoplanin was greater than the amount of A3-1 injected, suggesting that a metabolic or chemical detachment of N-acyl-glucosamine from teicoplanin components occurs, giving rise to A3-1 (3). Also, some new peaks with retention times between those of the A3 and A2 groups were detected by radiochromatography; those compounds were regarded as teicoplanin metabolites (7) .
The aim of this study was to detect, isolate, and characterize the teicoplanin metabolites in humans after i.v. administration of teicoplanin. HPLC assay. Teicoplanin in urine samples and column fractions, as well as the purified metabolites, were analyzed by HPLC by a method based on that of Riva et al. (13) . Analysis of teicoplanin in urine required preliminary extraction by affinity chromatography. The sample was loaded onto a D-alanyl-D-alanine-e-aminocaproyl-Sepharose CL-6B affinity column prepared in our laboratories. The resin volume in each column was 0.5 ml. Before use, the column was equilibrated with 10 ml of phosphate buffer (0.05 M; pH 7.4) containing 0.2 M NaCl. The resin was then washed with
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another 1 ml of the equilibrating buffer, and the eluate was discarded. Teicoplanin was desorbed from the affinity resin by eluting the column three times with 0.5 ml of 1.5% NH40H. The eluate (1.5 ml) was collected in a 2-ml volumetric flask and was brought up to volume with 1 M HCl. For HPLC, a Hewlett-Packard system connected to an HP 3357 computing system was used. The operating conditions were as follows: column, Erbasil C18 (5 ,um, 150 by 4.6 mm; Carlo Erba, Milano, Italy); column temperature, 30°C; flow rate, 1.5 ml/min; mobile phase A, acetonitrile-0.02 M NaH2PO4 Radioactivity determination. The radioactivity in urine and column eluates was measured by liquid scintillation spectrometry in a Packard 460C spectrometer, after the addition of Instagel scintillation cocktail (Packard). The radiochemical HPLC profiles were obtained by collecting the 0-to 45-min eluates in 10-s fractions.
Extraction and purification of metabolites from urine. . A Hewlett-Packard system with a UV detector (254 nm) was used. Acetonitrile was evaporated under vacuum from the eluates containing either metabolite 1 or 2. The metabolite 1 fraction was concentrated under vacuum, frozen, and lyophilized. The metabolite 2 fraction was loaded onto an additional D-alanyl-D-alanine-e-aminocaproyl-Sepharose CL-6B affinity resin (2 ml) and was suspended in 0.05 M phosphate buffer (pH 7.4) containing 0.2 M NaCl in order to concentrate the solution prior to lyophilization. Metabolite 2 was desorbed from the affinity resin by eluting with 1.5% NH40H until recovery of the radioactivity was complete. The eluate was brought to pH 7 with 10% formic acid, frozen, and lyophilized.
Mass spectroscopy. The fast atom bombardment spectra of metabolites 1 and 2 were obtained on a Kratos MS-50 double-focusing mass spectrometer with a 3,000-Da mass RESULTS Evidence of teicoplanin metabolites in urine. Figure 3 shows the HPLC tracing of a urine sample collected from one volunteer 24 to 48 h after the administration of radiola- beled teicoplanin. The presence of metabolites 1 and 2, which were particularly abundant in this sample (6% of total teicoplanin), was shown by both the UV and the radiochemical tracings. The administered teicoplanin did not contain these compounds (Fig. 2) . When the urine samples were pooled, the proportion of metabolites 1 and 2 was 2.7% of the total amount of teicoplanin administered. compounds were completely extracted from the urine; the radioactivity that was unadsorbed to the resin was 0.8% of the total radioactivity. All of the radioactivity was eluted from the column with acetone-water. Following evaporation of the acetone, some sediment had to be eliminated from the aqueous phase by centrifugation, with a loss of about 30% of the radioactivity. The aqueous phase underwent the second chromatographic step (affinity column), in which 96% of the loaded radioactivity was retained. After washing, it was completely eluted. In the third chromatographic step (silanized silica gel), teicoplanin-related compounds were completely retained by the resin. Upon gradient elution, two bands were separated. HPLC analysis of the pooled fractions showed that the smaller band contained the A3 components and the two metabolites and that the larger band contained the rest of the teicoplanin complex (A2 and related substances). The two metabolites were isolated from the smaller band as described above. The HPLC profile of teicoplanin under the conditions generally used (13) gave no indication of the relative amounts of the two metabolites because they coincided (Fig. 3) . When the metabolites were separated, the amount of metabolite 1 was four to five times that of metabolite 2. Structure assignment of metabolites 1 and 2. The fast atom bombardment mass spectra of the two metabolites were practically identical. That of metabolite 1 is shown in Fig. 4 . It is analogous to that of teicoplanin, showing two main groups of peaks: the molecular ion cluster [lowest isotopes of the (M + H)+ peak were 1894.7] and the fragment formed by the loss of acyl-glucosamine (M + H -acyl-glucosamine)+ at 1563.3. The latter was identical in mass to that of teicoplanin, while the (M + H)+ cluster was 16 units larger than the A2-2 and A2-3 components of teicoplanin. This indicates that the acyl-glucosamine part is modified in the metabolites, with the most likely change being hydroxylation of the alkyl chain.
The NMR spectra of metabolites 1 and 2 are shown in Fig.  5 and 6 , respectively. The interpretations of all the signals were done by using 1H-'H two-dimensional correlations through three bonds by COSY phase-sensitive with doublequantum-filter (COSYPHDQ) experiments and through three and four bonds by COSY with relayed coherence transfer (COSYRCT) experiments. From the results of these experiments and by comparison with data on teicoplanin in the literature (1, 10, 11) , it was found that both metabolites have the same structure as that shared by the five components of the teicoplanin complex, which differ only in the acyl chain. 2.02 1.43 1.14-1.26 1.44 Similarly, for the two metabolites, the high field part of 1H NMR spectrum unequivocally defines the acyl moiety.
(i) Metabolite 1. The triplet at 0.83 ppm is due to a CH3 coupled to a CH2 (1.26 ppm), the triplet at 2.02 ppm is due to a CH2 a to a C-O, and the multiplet at 1.43 is due to a CH2 i to a C-O. An interesting feature is that the broad signal of A2-2 at 1.14 to 1.26 ppm is split into two broad signals centered at 1.15 and 1.26 ppm; i.e., the peak at 1.15 ppm is due to three CH2 groups in a normal aliphatic chain, while the signal at 1.26 ppm is interpreted as being due to two CH2 groups that lie on either side of a CHOH moiety which exerts a deshielding effect on them. The existence of this CHOH moiety and its location along the chain was verified by the COSYRCT experiment, which showed the correlation between the terminal CH3 and the proton at 3.20 ppm, which is characteristic of a CHOH moiety. In conclusion, the attributions are schematized as follows: Table 1 reports the MICs for some staphylococcal, streptococcal, and enterococcal isolates. The activities of the two metabolites were similar, and they were less active than teicoplanin.
DISCUSSION
When administered i.v. to humans, the glycopeptide antibiotic teicoplanin undergoes minor metabolic biotransformations. As reported previously (3), the amount of the A3-1 component recovered in urine is 20% greater than that administered. This component represented only a minor percentage of the administered teicoplanin (7.1%), and its increase represents either some biotransformation of teicoplanin components to A3-1 or, more plausibly, a chemical transformation (9) .
Although the detection and characterization of metabolites 1 and 2 are important for understanding of the in vivo biotransformation of teicoplanin, the extent of metabolism to these compounds is minor (about 3%). Structural considerations suggest that they might derive from Q1-1 and Ql-2 hydroxylation of the linear fatty acid chain of component A2-3, whereas an origin from the branched fatty acid chain of the main component A2-2 appears very unlikely. Hydroxylation reactions, catalyzed by cytochrome P-450 monooxygenase systems, occur in the fl, fl-1, and other positions of medium-chain linear fatty acids and n-alkanes during in vitro or in vivo metabolism in mammals (15) . The absence of fQ hydroxylation of teicoplanin might be due to an effect of the drug on some specific isozymes of cytochrome P-450. Experiments on the metabolism of the single components are planned in order to clarify this point.
Some investigators have suggested that, unlike teicoplanin, vancomycin may be metabolized to a significant extent (6, 12, 14) . This is based on kinetic considerations, but no direct evidence of biotransformation has yet appeared.
